ドロキシドパ
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 起立性低血圧および食後低血圧の治療treatment of orthostatic and postprandial hypotension [show details]
…occur with midodrine. L-dihydroxyphenylserine (DOPS, droxidopa) is a synthetic amino acid, identical to levodopa but with an added hydroxyl group. After oral administration, droxidopa is decarboxylated to …
- 2. パーキンソン病とパーキンソン症候群への対症療法palliative approach to parkinson disease and parkinsonian disorders [show details]
…binders), and exercise. Pharmacologic therapy includes medications such as fludrocortisone, midodrine, droxidopa, and pyridostigmine. Slowed gastrointestinal motility is a prominent nonmotor feature of PD related…
- 3. パーキンソン病の非運動症状のマネージメントmanagement of nonmotor symptoms in parkinson disease [show details]
…treatments are reserved for symptomatic patients who do not respond to these measures. Options include droxidopa, fludrocortisone, and midodrine, though these may lead to supine hypertension . Pyridostigmine may…
- 4. 糖尿病性自律神経障害diabetic autonomic neuropathy [show details]
…severe supine hypertension, so patients should not use midodrine within six hours of bedtime. Droxidopa, an orally administered norepinephrine prodrug, has received regulatory approval in the United States …
- 5. 多系統萎縮症：予後および治療multiple system atrophy prognosis and treatment [show details]
…include the alpha-1 adrenergic agonist, midodrine, and the norepinephrine precursor, droxidopa. The efficacy of droxidopa was demonstrated in two small studies that included patients with MSA . Supine hypertension…
English Journal
- Managing autonomic dysfunction in Parkinson's disease: a review of emerging drugs.
- Kulshreshtha D, Ganguly J, Jog M.
- Expert opinion on emerging drugs. 2020 Mar;25(1)37-47.
- Array
- PMID 32067502
- State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson's disease.
- Quarracino C, Otero-Losada M, Capani F, Pérez-Lloret S.
- Expert opinion on pharmacotherapy. 2020 Mar;21(4)445-457.
- Array
- PMID 31957505
- Real-world droxidopa or midodrine treatment persistence in patients with neurogenic orthostatic hypotension or orthostatic hypotension.
- Kymes SM, Sullivan C, Jackson K, Raj SR.
- Autonomic neuroscience : basic & clinical. 2020 Feb;225()102659.
- Neurogenic orthostatic hypotension (nOH) is a subtype of orthostatic hypotension (OH) observed in the presence of neuropathy and is associated with increased risk of falling, impaired function, and poor quality of life. Droxidopa and midodrine are approved in the United States to treat symptomatic n
- PMID 32200263
Related Links
- L-threo-3,4-Dihydroxyphenylserine enhanced ocular dominance plasticity in adult cats N. Mataga, K. Imamura, Y. Watanabe, Neurosci. Lett. 1992, 142, 115. Restoration of norepinephrine and reversal of phenotypes in mice , 70
- L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
- L-threo-dihydroxyphenylserine (L-DOPS) is used for amelioration of DBH deficiency. Next: Trace metals Class Summary IV/SC copper in various formulations has been used to treat individuals with Menkes kinky hair disease ...
★リンクテーブル★
[★]
- 英
- droxidopa
- 同
- L-threo-dops L-スレオドプス L-threo-dihydroxyphenylserine
- 商
- ドプス
- 関
- 抗パーキンソン剤。パーキンソン病
概念
- ノルアドレナリンの前駆体であって、体内でL-aromatic amino acid decarboxylase(AADC)で脱炭酸され、norepinephrineに変換される。
- パーキンソン病患者ではノルアドレナリンが減少し、すくみ足やsudden transient freezing-upを改善すると言われている。
適応
副作用
[★]